We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Risk of Heart Attack Not Reduced by Antibiotics

By HospiMedica staff writers
Posted on 23 May 2005
A new study has shown that taking antibiotics for a year does not reduce the risk of a heart attack or other cardiac event in patients with stable coronary artery disease.

Since previous studies found the bacteria Chlamydia pneumoniae in the arterial plaque of patients with coronary artery disease, researchers wondered whether antiobiotcs could be used to treat the bacteria and thereby reduce the risk of cardiac events. About 50% of U.S. adults have been exposed to C pneumoniae sometime in their lives.

The researchers randomly assigned 4,012 men and women to receive either once-weekly doses of azithromycin or placebo for one year. After an average follow-up of 3.9 years, there was no significant reduction of cardiac events, defined as heart attack, unstable angina, angioplasty, or cardiac surgery among participants who received the antibiotic compared to those given placebo. The treatment also showed no affect on total mortality or on the incidence of stroke. The men and women in the study had stable coronary artery disease following a previous cardiac event such as a heart attack, angioplasty, or bypass surgery.

"Although antibiotic treatment of patients with clinical coronary heart disease is not helpful, the ACES [Azithromycin and Coronary Events Study] study was not designed to find the role of C pneumoniae in the cause or progression of coronary heart disease,” explained J. Thomas Grayston, M.D., professor of epidemiology, University of Washington (Seattle, USA), and the study's principal investigator.

The study was funded by the U.S. National Heart, Lung, and Blood Institute (Bethesda, MD, USA), and the results were reported in April 21, 2005, issue of The New England Journal of Medicine.




Related Links:
University of Washington

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Point-Of-Care Terminal
POC-824
New
Surgical Booms
AIRport

Latest Critical Care News

Breakthrough Technique Stops Irregular Heartbeats

AI Model Accurately Predicts Progression of Autoimmune Disease

AI Predicts and Identifies Subtypes of Type 2 Diabetes from Continuous Blood Glucose Monitor